| 1 |
杨佰侠，林祥宏，李涛, 等. 脑膜炎败血黄杆菌体外抗药活性及金属β内酰胺酶基因型研究[J]. 临床输血与检验, 2008, 10(2): 114-118.
|
| 2 |
石青峰，高玲. ICU脑膜炎败血黄杆菌所致医院获得性感染的临床特征及耐药性分析[J]. 国际检验医学杂志, 2013, 34(1): 27-28, 31.
|
| 3 |
Hsu MS, Liao CH, Huang YT, et al. Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica(Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999-2006[J]. Eur J Clin Microbiol Infect Dis, 2011, 30 (10): 1271-1278.
|
| 4 |
Kirby JT, Sader HS, Walsh TR, et al. Antimicrobial susceptibility and epidemiology of a worldwide collection of chryseobacterium spp.: report from the SENTRY antimicrobial surveillance program (1997-2001)[J]. J Clini Microbiol, 2004, 42 (1): 445-448.
|
| 5 |
桑福德. 热病——桑福德抗微生物治疗指南[M]. 范洪伟译. 新译第46版. 北京: 中国协和医科大学出版社, 2017: 70.
|
| 6 |
Haruta T, Nishio T, Kobayashi Y. Transferability of ta-zobactam/piperacillin (TAZ/PIPC) to cerebrospinal fluid of rabbit with meningitis caused by Staphylococcus aureus[J]. Jpn J Antibiot, 1998, 51 (6): 432-436.
|
| 7 |
Fukasawa C, Hoshino T, Kutsuna S, et al. Concentration of tazobactam/piperacillin in the cerebrospinal fluid of patients with Haemophilus influenzae type B meningitis[J]. Kansenshogaku Zasshi, 2013, 87 (5): 590-595.
|
| 8 |
Tak V, Mathur P, Varghese P, et al. Elizabethkingia meningoseptica: an emerging pathogen causing meningitis in a hospitalized adult trauma patient[J]. Indian J Med Microbiol, 2013, 31 (3): 293-295.
|
| 9 |
Amer MZ, Bandey M, Bukhari A, et al. Neonatal meningitis caused by Elizabethkingia meningoseptica in Saudi Arabia[J]. J Infect Dev Ctries, 2011, 5 (10): 745-747.
|
| 10 |
张晓静. 新生儿泛耐药性脑膜脓毒金黄杆菌败血症合并脑炎成功治愈1例病例报告[J/CD]. 世界最新医学信息文摘（电子版）, 2013(6): 430, 435.
|
| 11 |
Patel K, Goldman JL. Safety concerns surrounding qu-inolone use in children[J]. J Clin Pharmacol, 2016, 56 (9): 1060-1075.
|
| 12 |
Yabe K, Satoh H, Ishii Y, et al. Early pathophysiologic feature ofarthropathy in juvenile dogs induced by ofloxacin, a quinolone antimicrobialagent[J]. Vet Pathol, 2004, 41 (6): 673-681.
|
| 13 |
Schaad UB, Salam MA, Aujard Y, et al. Use of fIuoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission[J]. Pediatr Infect Dis J, 1995, 14 (1): 1-9.
|
| 14 |
Committee on Infectious Diseases. The use of systemic fluoroquinolones[J]. Pediatrics, 2006, 118 (3): 1287-1292.
|
| 15 |
Pandolfini C, Marco S, Paolo M, et al. The use of ciprofloxacin and fluconazole in Italian neonatal intensive care units: a nationwide survey[J]. BMC Pediatr, 2013 (13): 5.
|
| 16 |
Ahmed AS, Khan NZ, Saha SK, et al. Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development[J]. Pediatr Infect Dis J, 2006, 25 (12): 1137-1141.
|
| 17 |
Wildenbeest JG, Said I, Jaeger B, et al. Neonate with Mycoplasma hominis meningoencephalitis given moxifloxacin[J]. Lancet Infect Dis, 2016, 16 (11): e261-e266.
|
| 18 |
Pandolfini C, Kaguelidou F, Sequi M, et al. Wide intra-and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections[J]. Eur J Clin Pharmacol, 2013, 69 (4): 1031-1036.
|
| 19 |
Newby BD, Timberlake KE, Lepp LM, et al. Levoflo-xacin use in the neonate: a case series[J]. J Pediatr Pharmacol Ther, 2017, 22 (4): 304-313.
|
| 20 |
Schlüter G. Ciprofloxacin: review of potential toxicologic effects[J]. Am J Med, 1987, 82 (4): 91-93.
|
| 21 |
Linseman DA, Hampton LA, Branstetter DG. Quinolone - induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin[J]. Fundam Appl Toxicol, 1995, 28 (1): 59-64.
|
| 22 |
Zhao W, Hill H, Le Guellec C, et al. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age[J]. Antimicrob Agents Chemother, 2014, 58 (11): 6572-6580.
|